WEST PHARMACEUTICAL SERVICES INC Quarterly Net Income (Loss) Attributable to Parent in USD from Q2 2010 to Q4 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
West Pharmaceutical Services Inc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q2 2010 to Q4 2024.
  • West Pharmaceutical Services Inc Net Income (Loss) Attributable to Parent for the quarter ending December 31, 2024 was $130M, a 5.04% decline year-over-year.
  • West Pharmaceutical Services Inc Net Income (Loss) Attributable to Parent for the twelve months ending December 31, 2024 was $493M, a 17% decline year-over-year.
  • West Pharmaceutical Services Inc annual Net Income (Loss) Attributable to Parent for 2024 was $493M, a 17% decline from 2023.
  • West Pharmaceutical Services Inc annual Net Income (Loss) Attributable to Parent for 2023 was $593M, a 1.28% increase from 2022.
  • West Pharmaceutical Services Inc annual Net Income (Loss) Attributable to Parent for 2022 was $586M, a 11.5% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2024 $493M $130M -$6.9M -5.04% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-18
Q3 2024 $500M $136M -$25.3M -15.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-10-24
Q2 2024 $525M $111M -$43.8M -28.2% Apr 1, 2024 Jun 30, 2024 10-Q 2024-10-24
Q1 2024 $569M $115M -$24.7M -17.6% Jan 1, 2024 Mar 31, 2024 10-Q 2024-10-24
Q4 2023 $593M $137M +$34M +33% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-18
Q3 2023 $559M $161M +$40.7M +33.7% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-24
Q2 2023 $519M $155M -$33.4M -17.7% Apr 1, 2023 Jun 30, 2023 10-Q 2024-10-24
Q1 2023 $552M $140M -$33.8M -19.4% Jan 1, 2023 Mar 31, 2023 10-Q 2024-10-24
Q4 2022 $586M $103M -$44.7M -30.3% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-18
Q3 2022 $631M $121M -$55M -31.3% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-26
Q2 2022 $686M $189M +$1.2M +0.64% Apr 1, 2022 Jun 30, 2022 10-Q 2023-10-26
Q1 2022 $684M $174M +$22.6M +14.9% Jan 1, 2022 Mar 31, 2022 10-Q 2023-10-26
Q4 2021 $662M $148M +$49.3M +50.1% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 $613M $176M +$93.3M +113% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 $519M $187M +$96.1M +105% Apr 1, 2021 Jun 30, 2021 10-Q 2022-10-27
Q1 2021 $423M $151M +$76.9M +103% Jan 1, 2021 Mar 31, 2021 10-Q 2022-10-27
Q4 2020 $346M $98.4M +$34.5M +54% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 $312M $82.3M +$26M +46.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-28
Q2 2020 $286M $91.2M +$25.1M +38% Apr 1, 2020 Jun 30, 2020 10-Q 2021-10-28
Q1 2020 $261M $74.3M +$18.9M +34.1% Jan 1, 2020 Mar 31, 2020 10-Q 2021-10-28
Q4 2019 $242M $63.9M Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 $56.3M Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 $66.1M Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 $55.4M Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q1 2012 $29.2M +$9.6M +49% Jan 1, 2012 Mar 31, 2012 10-Q 2012-05-04
Q3 2011 $16.9M -$900K -5.06% Jul 1, 2011 Sep 30, 2011 10-Q 2011-11-07
Q2 2011 $20.1M -$1.6M -7.37% Apr 1, 2011 Jun 30, 2011 10-Q/A 2011-08-08
Q1 2011 $19.6M Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-04
Q3 2010 $17.8M Jul 1, 2010 Sep 30, 2010 10-Q 2011-11-07
Q2 2010 $21.7M Apr 1, 2010 Jun 30, 2010 10-Q/A 2011-08-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.